First-line anti-VEGF plus EGFR-TKI in EGFR-mutant NSCLC: adding the ARTEMIS trial to the puzzle of current evidence

被引：3
|
作者：
Hafner, Susanne [1 ]
机构：
[1] Ulm Univ, Inst Pharmacol Nat Prod & Clin Pharmacol, D-89081 Ulm, Germany
来源：
SIGNAL TRANSDUCTION AND TARGETED THERAPY | 2021年 / 6卷 / 01期
关键词：
CELL LUNG-CANCER; BEVACIZUMAB; ERLOTINIB; MULTICENTER;
D O I：
10.1038/s41392-021-00813-y
中图分类号：
Q5 [生物化学]; Q7 [分子生物学];
学科分类号：
071010 ; 081704 ;
摘要：
引用
收藏
页数：3
相关论文
共 50 条
  • [41] Tepotinib plus osimertinib for EGFR-mutant NSCLC with resistance to first-line osimertinib due to MET amplification (METamp): INSIGHT 2
    Wu, Y-L.
    Dooms, C.
    Nadal, E.
    Raskin, J.
    Demedts, I.
    Mazieres, J.
    Wislez, M.
    Abdul Shukor, S.
    Tho, L. M.
    Wang, C-C.
    Viteri, S.
    Le, X.
    How, S. H.
    Tan, D.
    Takeda, M.
    Veillon, R.
    Karachaliou, N.
    Ellers-Lenz, B.
    Smit, E. F. F.
    ANNALS OF ONCOLOGY, 2021, 32 : S1036 - S1036
  • [42] Tepotinib plus osimertinib in EGFR-mutant NSCLC with MET amplification following first-line osimertinib: INSIGHT 2 primary analysis
    Le, Xiuning
    Kim, Tae Min
    Guarneri, Valentina
    Voon, Pei Jye
    Lim, Boon Khaw
    Yang, Jinji
    Wislez, Marie
    Huang, Cheng
    Liam, Chong Kim
    Mazieres, Julien
    Lye Mun Tho
    Hayashi, Hidetoshi
    Nguyen Nhung
    Chia, Puey Ling
    De Marinis, Fillippo
    Raskin, Jo
    Zhou, Qinghua
    Finochhiaro, Giovanna
    Tan, Daniel
    Brutlach, Sabine
    O'Brate, Aurora
    Adrian, Svenja
    Berghoff, Karin
    Ellers-Lenz, Barbara
    Karachaliou, Niki
    Wu, Yi-Long
    MOLECULAR CANCER THERAPEUTICS, 2023, 22 (12)
  • [43] Phase II study of erlotinib plus onartuzumab as first-line treatment for patients with MET-positive and EGFR-mutant NSCLC
    Sakai, Hiroshi
    Kishi, Kazuma
    Seto, Takashi
    Kozuki, Toshiyuki
    Nishio, Makoto
    Imamura, Fumio
    Nokihara, Hiroshi
    Satouchi, Miyako
    Tahata, Takashi
    Nakagawa, Kazuhiko
    ANNALS OF ONCOLOGY, 2015, 26 : 82 - 82
  • [44] Toripalimab plus chemotherapy as second-line treatment in previously EGFR-TKI treated patients with EGFR-mutant-advanced NSCLC: a multicenter phase-II trial
    Tao Jiang
    Pingyang Wang
    Jie Zhang
    Yanqiu Zhao
    Jianying Zhou
    Yun Fan
    Yongqian Shu
    Xiaoqing Liu
    Helong Zhang
    Jianxing He
    Guanghui Gao
    Xiaoqian Mu
    Zhang Bao
    Yanjun Xu
    Renhua Guo
    Hong Wang
    Lin Deng
    Ningqiang Ma
    Yalei Zhang
    Hui Feng
    Sheng Yao
    Jiarui Wu
    Luonan Chen
    Caicun Zhou
    Shengxiang Ren
    Signal Transduction and Targeted Therapy, 6
  • [45] WHICH DO NSCLC PATIENTS WITH EGFR MUTATION PREFER AS A FIRST-LINE THERAPY, EGFR-TKI OR CHEMOTHERAPY? A VIGNETTES STUDY (LOGIK0903)
    Iwama, Eiji
    Takayama, Koichi
    Suetsugu, Takayuki
    Ebi, Noriyuki
    Fukuda, Minoru
    Nagata, Nobuhiko
    Tsuruta, Nobuko
    Ishida, Masayuki
    Tokunaga, Shoji
    Sasaki, Jiichiro
    Ichinose, Yukito
    RESPIROLOGY, 2013, 18 : 29 - 29
  • [46] Antacid and de novo brain metastases in EGFR-mutant NSCLC patients treated with first-line, first-generation EGFR-TKIs
    Chen, Y-M.
    Lin, M-C.
    Lai, C-H.
    Fang, W-F.
    Chang, H-C.
    Wang, C-C.
    Tseng, C-C.
    JOURNAL OF THORACIC ONCOLOGY, 2016, 11 (04) : S132 - S132
  • [47] Toripalimab plus chemotherapy as second-line treatment in previously EGFR-TKI treated patients with EGFR-mutant-advanced NSCLC: a multicenter phase-II trial
    Jiang, Tao
    Wang, Pingyang
    Zhang, Jie
    Zhao, Yanqiu
    Zhou, Jianying
    Fan, Yun
    Shu, Yongqian
    Liu, Xiaoqing
    Zhang, Helong
    He, Jianxing
    Gao, Guanghui
    Mu, Xiaoqian
    Bao, Zhang
    Xu, Yanjun
    Guo, Renhua
    Wang, Hong
    Deng, Lin
    Ma, Ningqiang
    Zhang, Yalei
    Feng, Hui
    Yao, Sheng
    Wu, Jiarui
    Chen, Luonan
    Zhou, Caicun
    Ren, Shengxiang
    SIGNAL TRANSDUCTION AND TARGETED THERAPY, 2021, 6 (01)
  • [48] Adding chemotherapy to TKI: can we improve first-line treatment for EGFR-mutated NSCLC patients?
    Passiglia, Francesco
    Russo, Antonio
    TRANSLATIONAL CANCER RESEARCH, 2016, 5 : S1413 - S1416
  • [49] BUDGETARY IMPACT OF FIRST-LINE TREATMENT FOR METASTATIC COLORECTAL CANCER BASED ON XELOX plus ANTI-VEGF OR XELOX plus ANTI-EGFR
    Gomez, E.
    Torrecillas, L.
    Cervantes, L.
    VALUE IN HEALTH, 2011, 14 (07) : A543 - A543
  • [50] Treatment Patterns and Clinical Outcomes in Patients with EGFR-mutant NSCLC after Progression on First-Line Osimertinib
    Robinson, N. D.
    Zhan, P.
    Udelsman, B.
    Boffa, D. J.
    Goldberg, S. B.
    JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (11) : S364 - S364
12345